Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

• Status: Suspended
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This randomized pilot clinical trial studies how well propranolol hydrochloride works in treating patients with prostate cancer who are undergoing surgery. When stressed, the body makes a molecule that may prevent tumor cells from dying, and propranolol hydrochloride may affect the signals in cells that cause tumor cells survival and death.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Collaborator: National Cancer Institute (NCI)
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• Diagnosis of prostate cancer undergoing prostatectomy

• Individuals able to understand and willing to sign an Institutional Review Board (IRB)-approved informed consent document

Exclusion Criteria:

• Men taking propranolol on a daily for any reason are excluded

• Men with baseline systolic blood pressure (SBP) < 110 or heart rate (HR) < 60

• Men unable to swallow pills

• History of current or past medical or psychiatric illness that would make participation difficult or not feasible at the discretion of the principal investigator or co-investigators